Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients.

ABSTRACT:

Background

Lack of data on balancing bleeding and thrombosis risk causes uncertainty about restarting anticoagulants after major bleeding. Anticoagulant reversal trials offer prospectively gathered data after major bleeding with well-documented safety events and restarting behavior.

Objectives

To examine the relationship of restarting anticoagulation with thrombosis, rebleeding, and death.

Methods

This is a posthoc analysis of a prospective factor Xa inhibitor reversal study at 63 centers in North America and Europe. We compared outcomes of restarted patients with those not restarted using landmark and time-dependent Cox proportional hazards models. Outcomes included thrombotic and bleeding events and death and a composite of all three.

Results

Of 352 patients

SUBMITTER: Milling TJ 

PROVIDER: S-EPMC8322590 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature